Form 4: Pressure BioSciences Director Acquires Shares Through Interest Payment

Director Michael S Urdea acquired 2,872 shares of Pressure BioSciences Inc. common stock on March 27, 2024, through interest paid on convertible preferred stock.

Summary

• On March 27, 2024, Michael S Urdea, a director of Pressure BioSciences Inc., acquired 2,872 shares of common stock.
• The acquisition was a result of interest paid on convertible preferred stock.
• The price per share was $0.16.
• Following the transaction, Urdea directly owns 33,159 shares of Pressure BioSciences Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, but insider buying can be viewed slightly positively.

Positives

• A director increasing their holdings could be seen as a positive signal about their confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency into the trading activities of individuals with access to non-public information.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Pressure BioSciences Inc, PBIO, Form 4, Michael S Urdea, Director, Stock Acquisition, Convertible Preferred Stock, Interest Payment, Beneficial Ownership